The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Dec. 19, 2016
Applicant:

Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);

Inventors:

Yuri Bukhtiyarov, Boothwyn, PA (US);

Salvacion Cacatian, Conshohocken, PA (US);

Lawrence Wayne Dillard, Yardley, PA (US);

Cornelia Dorner-Ciossek, Ingelheim am Rhein, DE;

Klaus Fuchs, Ingelheim am Rhein, DE;

Lanqi Jia, Horsham, PA (US);

Deepak S. Lala, Lower Gwynedd, PA (US);

Angel Morales-Ramos, Blue Bell, PA (US);

Jonathan Reeves, Ridgefield, CT (US);

Suresh B. Singh, Kendall Park, NJ (US);

Shankar Venkatraman, Landsdale, PA (US);

Zhenrong Xu, Chalfont, PA (US);

Jing Yuan, Lansdale, PA (US);

Yi Zhao, Blue Bell, PA (US);

Yajun Zheng, Hockessin, DE (US);

Georg Rast, Ingelheim am Rheim, DE;

Assignee:

Vitae Pharmaceuticals, Inc., Madison, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 405/06 (2006.01); A61K 31/506 (2006.01); C07D 235/02 (2006.01); C07D 403/06 (2006.01); C07D 407/06 (2006.01); C07C 49/697 (2006.01); C07C 49/747 (2006.01); C07C 49/755 (2006.01); C07C 229/50 (2006.01); C07C 255/47 (2006.01); C07C 313/06 (2006.01); C07C 331/14 (2006.01); A61K 31/4184 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/4184 (2013.01); C07C 49/697 (2013.01); C07C 49/747 (2013.01); C07C 49/755 (2013.01); C07C 229/50 (2013.01); C07C 255/47 (2013.01); C07C 313/06 (2013.01); C07C 331/14 (2013.01); C07D 235/02 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 407/06 (2013.01);
Abstract

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.


Find Patent Forward Citations

Loading…